Top Markets
#1 Akedo Akedo +57.36%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.30%
#4 Cross Cross +41.98%
#5 OVERTAKE OVERTAKE +41.07%
#6 Velvet Velvet +35.30%
#7 Black Phoenix Black Phoenix +33.82%
#8 Cap Cap +21.97%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.43%
#10 Bitway Bitway +11.98%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Molecular Pharmacology (USA), Ltd. Molecular Pharmacology (USA), Ltd.

Molecular Pharmacology (USA), Ltd.

MLPH
Rank in Stocks #39112
As a development-stage company, Molecular Pharmacology (USA) Limited (MLPH) is... As a development-stage company, Molecular Pharmacology (USA) Limited (MLPH) is dedicated to the creation and market introduction of solutions for pain and inflammation, with a primary focus on the Australian and United States markets. Through its subsidiary, Molecular Pharmacology Pty. Ltd., it is advancing an analgesic and anti-inflammatory molecule called Tripeptofen, designed to alleviate common daily pain. These products are offered in diverse dosage forms, formulations, and packaging options to suit various needs. MLPH's marketing strategy involves leveraging pharmaceutical distributors and forging collaborative partnerships with companies in the United States and Europe. Additionally, the company maintains an agreement with Dermatology Development Corporation to jointly develop and market a suite of therapeutic, cosmetic, and cosmeceutical items derived from the ThermaLIFE product line and its core active component. Headquartered in Perth, Australia, Molecular Pharmacology (USA) Limited operates as a subsidiary of PharmaNet Group Limited.
Share Price
$0.0322
Last synced: 2026-08-12
Market Cap
$643.71K
Change (1 day)
0.00%
Change (1 year)
544.00%
Country
AU
Trade Molecular Pharmacology (USA), Ltd. (MLPH)

Category

Healthcare
Number of shares outstanding for Molecular Pharmacology (USA), Ltd. (MLPH)
Number of shares outstanding as of August 2026: 0
According to Molecular Pharmacology (USA), Ltd. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Molecular Pharmacology (USA), Ltd. (MLPH) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 0.00 -
BE